Abbott Laboratories
NYSE:ABT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
111.1
140.22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Abbott Laboratories
Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment.
Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.
Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment.
Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.
Organic Sales Growth: Abbott delivered 7.5% organic sales growth in Q3, excluding COVID test sales, led by double-digit growth in Medical Devices.
EPS Performance: Earnings per share rose to $1.30, up high single digits year-over-year and in line with consensus expectations.
Strong Device Momentum: Medical Devices sales grew 12.5%, with standout growth in Diabetes Care, Electrophysiology, Cardiac Rhythm Management, Heart Failure, and Structural Heart.
Diagnostics Headwinds: Diagnostics saw modest growth; China pricing and volume pressures remain, but recovery is expected as headwinds diminish in 2025.
Guidance Maintained: Management remains confident in delivering high single-digit organic sales growth and double-digit EPS growth into 2026.
Pipeline & Innovation: New product launches, particularly in diabetes and electrophysiology, are expected to fuel future growth.
Margins and Tariffs: Gross margin was 55.8%, impacted by tariffs, but management is focused on further expansion and mitigation.
China: China remains important, though growth is now mid-single digits outside of diagnostics; management expects stable outlook going forward.
Management
Robert B. Ford is the Chairman of the Board and Chief Executive Officer of Abbott Laboratories, a global healthcare company. Ford joined Abbott in 1996 and has held various roles with increasing responsibilities throughout his career. Before becoming CEO in 2020, he served as President and Chief Operating Officer. Ford has played a pivotal role in Abbott's growth and innovation strategy, particularly in expanding the company's leadership in diagnostics, nutrition, medical devices, and branded generic pharmaceuticals. He was instrumental in the company's work on developing and distributing rapid COVID-19 tests, which have been critical in managing the global pandemic. Ford is known for his focus on innovation, operational excellence, and creating products that improve quality of life. Under his leadership, Abbott continues to be recognized for its contributions to healthcare and its strong business performance. He holds a bachelor’s degree from Boston College and an MBA from the University of California, Berkeley.
Ford has played a pivotal role in Abbott's growth and innovation strategy, particularly in expanding the company's leadership in diagnostics, nutrition, medical devices, and branded generic pharmaceuticals. He was instrumental in the company's work on developing and distributing rapid COVID-19 tests, which have been critical in managing the global pandemic.
Ford is known for his focus on innovation, operational excellence, and creating products that improve quality of life. Under his leadership, Abbott continues to be recognized for its contributions to healthcare and its strong business performance. He holds a bachelor’s degree from Boston College and an MBA from the University of California, Berkeley.
Philip P. Boudreau is a noted executive with extensive experience in the pharmaceutical and healthcare industries. As an officer at Abbott Laboratories, he has been actively involved in various strategic and operational roles. Abbott Laboratories, being a global healthcare leader, focuses on areas such as diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. Boudreau's contributions often emphasize enhancing operational efficiencies, expanding market reach, and fostering innovation to meet the evolving needs of patients and healthcare providers. His leadership style is characterized by a commitment to sustainable growth and developing high-performance teams. His career at Abbott Laboratories reflects a blend of strategic acumen and dedication to advancing healthcare solutions on a global scale.
Hubert L. Allen, J.D., serves as an executive at Abbott Laboratories, where he holds the position of Executive Vice President, General Counsel, and Secretary. In this role, he is responsible for overseeing Abbott's global legal affairs and policies. With a strong background in corporate law, Allen ensures that the company's activities are in compliance with legal and regulatory requirements. He provides strategic legal guidance to support Abbott’s business operations and growth initiatives. Allen has been with Abbott for several years and has held various positions within the organization, gaining extensive experience in legal and business matters. His expertise in healthcare law, corporate governance, and litigation has been instrumental in navigating the complex legal landscape of the pharmaceutical and medical device industries. Prior to joining Abbott, Hubert L. Allen practiced law at a major law firm, where he focused on corporate and securities law. His contributions are vital to supporting not only the legal strategy of Abbott but also its overall business objectives.
Allen has been with Abbott for several years and has held various positions within the organization, gaining extensive experience in legal and business matters. His expertise in healthcare law, corporate governance, and litigation has been instrumental in navigating the complex legal landscape of the pharmaceutical and medical device industries. Prior to joining Abbott, Hubert L. Allen practiced law at a major law firm, where he focused on corporate and securities law.
His contributions are vital to supporting not only the legal strategy of Abbott but also its overall business objectives.
Daniel Gesua Sive Salvadori is a notable executive at Abbott Laboratories, a global healthcare company. As of his latest roles, he has served as the Executive Vice President of the Established Pharmaceuticals division. Salvadori has been with Abbott since 2005, bringing with him a wealth of experience in management and leadership roles within the pharmaceutical industry. Throughout his tenure at Abbott, Salvadori has been instrumental in driving the growth and success of the company’s established pharmaceuticals segment, which focuses on branded generic medicines. This division is significant for Abbott, especially in key markets across Asia, Latin America, Russia, and other emerging regions. Salvadori's leadership style is marked by strategic vision and a strong focus on expanding Abbott's market presence in global pharmaceutical markets. His work has helped the company effectively navigate the challenges of the healthcare industry while identifying opportunities for innovation and expansion. With a career spanning over several decades in pharmaceuticals, Salvadori is recognized for his expertise in global business strategies and operational efficiencies. His contributions to Abbott have been integral to the company's sustained growth and its ability to deliver healthcare solutions worldwide.
Throughout his tenure at Abbott, Salvadori has been instrumental in driving the growth and success of the company’s established pharmaceuticals segment, which focuses on branded generic medicines. This division is significant for Abbott, especially in key markets across Asia, Latin America, Russia, and other emerging regions.
Salvadori's leadership style is marked by strategic vision and a strong focus on expanding Abbott's market presence in global pharmaceutical markets. His work has helped the company effectively navigate the challenges of the healthcare industry while identifying opportunities for innovation and expansion.
With a career spanning over several decades in pharmaceuticals, Salvadori is recognized for his expertise in global business strategies and operational efficiencies. His contributions to Abbott have been integral to the company's sustained growth and its ability to deliver healthcare solutions worldwide.
Lisa D. Earnhardt is a prominent figure in the medical device industry and has held significant leadership roles, including being part of Abbott Laboratories. She served as the Executive Vice President of Medical Devices at Abbott, where she was instrumental in driving growth and innovation in the company’s extensive medical device portfolio. Before joining Abbott in 2019, Earnhardt was the President and CEO of Intersect ENT, a medical technology company, where she successfully led the company through various phases of development and commercialization. Her career is marked by vast experience in the healthcare sector, having held roles at Boston Scientific, where she was involved in various functions including sales, marketing, and general management. Earnhardt's leadership style is characterized by her focus on customer-centric solutions and advancing healthcare through innovative technology. She holds a Bachelor’s degree in Industrial Engineering from Stanford University and an MBA from Harvard Business School. Earnhardt is recognized not only for her professional achievements but also for her commitment to enhancing patient care and improving health outcomes through cutting-edge medical solutions. Her contributions have significantly impacted the medical devices field, both at Abbott and in her previous roles.
Her career is marked by vast experience in the healthcare sector, having held roles at Boston Scientific, where she was involved in various functions including sales, marketing, and general management. Earnhardt's leadership style is characterized by her focus on customer-centric solutions and advancing healthcare through innovative technology. She holds a Bachelor’s degree in Industrial Engineering from Stanford University and an MBA from Harvard Business School.
Earnhardt is recognized not only for her professional achievements but also for her commitment to enhancing patient care and improving health outcomes through cutting-edge medical solutions. Her contributions have significantly impacted the medical devices field, both at Abbott and in her previous roles.
Sabina Ewing is a recognized leader in the technology and pharmaceutical industries, currently serving as the Chief Information Officer (CIO) and Vice President of Business and Technology Services at Abbott Laboratories. With a strong background in leveraging technology for strategic business growth, Ewing oversees the implementation of advanced IT solutions to enhance Abbott's various healthcare and research operations. Her role includes ensuring that technology initiatives align with the company's goals of innovation and efficiency within the healthcare sector. Before joining Abbott, Ewing held significant leadership roles at Pfizer, where she gained extensive experience in digital transformation and IT strategy implementation. Her leadership style is characterized by a focus on collaboration, innovation, and a commitment to driving results through technological advancements. Ewing's contributions to Abbott Laboratories illustrate her deep expertise in IT and her commitment to improving outcomes in the healthcare industry through innovative technology solutions.
Before joining Abbott, Ewing held significant leadership roles at Pfizer, where she gained extensive experience in digital transformation and IT strategy implementation. Her leadership style is characterized by a focus on collaboration, innovation, and a commitment to driving results through technological advancements. Ewing's contributions to Abbott Laboratories illustrate her deep expertise in IT and her commitment to improving outcomes in the healthcare industry through innovative technology solutions.
Erica L. Battaglia currently serves as the Assistant Corporate Secretary at Abbott Laboratories. In her role, she is responsible for overseeing corporate governance and ensuring compliance with regulatory and legal standards. Erica plays a crucial role in facilitating communication between the company's board of directors and its executives, while also managing important documentation and records related to board activities. Her expertise in corporate governance and her attention to detail help uphold the integrity and efficiency of Abbott's corporate operations.
As of my latest information, there is no widely available public biography or detailed professional profile for a "Mr. Christopher J. Scoggins" associated with Abbott Laboratories. It's possible that he may not be a high-profile executive or public figure within the company. For accurate and detailed information, it would be best to consult official company communications, press releases, or directly contact Abbott Laboratories. If you have any additional context or a different name spelling, that might help in finding the right individual. If Mr. Scoggins is a recent appointee or a less publicly known figure, information may be limited or not widely disseminated through typical public channels.
If Mr. Scoggins is a recent appointee or a less publicly known figure, information may be limited or not widely disseminated through typical public channels.
Mary K. Moreland is an accomplished executive renowned for her leadership at Abbott Laboratories, where she serves as the Executive Vice President, General Counsel, and Secretary. In this capacity, she oversees Abbott's global legal affairs and compliance operations, ensuring that the company navigates complex regulatory environments efficiently. Her extensive legal expertise is backed by her prior experience in both corporate and private practice, where she honed her skills in managing multifaceted legal and regulatory challenges. Under her stewardship, Abbott Laboratories has maintained exemplary standards of legal compliance and governance. Moreland's role is integral to upholding the company's reputation and supporting its strategic objectives on a global scale.
